By using our website, you are agreeing to cookies being stored and Google Analytics being used on your device in order to offer the best possible service. You can find more information on thishere.
Austria.
Dynamic Business Location.

New IMP building: International research center opens in Vienna

opening ceremony at IMP © IMP

Philipp von Lattorff explains that Boehringer Ingelheim, in its capacity as a family-owned company, has the financial means to support basic research which may first lead to the development of new drugs in the long run. “IMP is the most important investment of Boehringer Ingelheim in basic research”, says the Managing Director of Boehringer Ingelheim RCV.

About IMP

The Research Institute of Molecular Pathology (IMP) in Vienna is a basic biomedical research institute largely sponsored by the international Boehringer Ingelheim group of companies With over 200 scientists from 40 nations, the IMP is committed to scientific discovery of fundamental molecular and cellular mechanisms in order to provide detail knowledge of complex biological phenomena. The IMP is a founding member of the Vienna Biocenter, Austria’s beacon in the international elite of top molecular-biological research.

About Boehringer Ingelheim Regional Center Vienna

The Boehringer Ingelheim Regional Center Vienna is responsible for Boehringer Ingelheim’s business with prescription drugs and animal medicines in Austria and over 30 other countries in Central and Eastern Europe, Central Asia, Switzerland and Israel. Moreover, the entire clinical research of the region is managed from Vienna. Vienna is the center for cancer research and also a location for biopharmaceutical research, development and production in the Group. Boehringer Ingelheim is also involved in basic research and is represented in this field by the Research Institute of Molecular Pathology Vienna (IMP). Thus, Boehringer Ingelheim is among Austria’s most research intensive pharmaceutical companies. The Regional Center Vienna generated net sales of EUR 760.2 million in the business year 2015 and employed 3,403 employees in the Central and Eastern European region, 1,501 of whom are in Austria.

Share on Facebook Share on Facebook Share on Twitter Share on Twitter Share on Linkedin Share on Linkedin

Testimonials

Events

Meet us at events, seminars and trade shows - worldwide.

  • ABA's Open Day 2021: Austria - Your ICT and Innovation Hub in the Heart of Europe

    11 March 2021/ 09.00am + 05.00 pm, Online Conference

  • Meet us @ International Machinery Forum 2021 - The Factory of Tomorrow

    11.03 - 12.03 2021, Online Conference

Austria Map

Find the perfect location for your company

The new Amazon distribution center in Großebersdorf is our first logistics site in Austria It will enable us to create additional and more flexible delivery capacities for the benefit of customers. We feel that we are in good hands, also thanks to the support of ABA – Invest in Austria.

Amazon

amazon.de
More testimonials

news from the business location Austria

OMV and Kommunalkredit invest in the production of green hydrogen

The Austrian oil and gas company OMV and Kommunalkredit Austria AG (Kommunalkredit) have announced a joint investment in the construction of Austria’s largest electrolysis plant to be located in the OMV Schwechat Refinery.

Evotec SE

Evotec is an active substance research company which rapidly presses ahead with innovative product approaches on the basis of development partnerships with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists.

More news All blog posts